Arbor Pharmaceuticals
As of the edition of 20 October 2026, Arbor Pharmaceuticals runs 12 drugs, 7 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- XenoPort, Inc.: acquired in 2016
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 5 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Acetylcysteine | none listed | 0 |
| Ivermectin | none listed | 0 |
| Triptorelin | none listed | 0 |
| Amphetamine | none listed | 2 |
| Gabapentin enacarbil | Ends 2026 (patent) | 2 |
| Nimodipine | none listed | 8 |
| Sotalol | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| GABBR1 Gamma-aminobutyric acid type B receptor subunit 1 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Arbor Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 12 trials led
- Mental health: 9 trials led
- Digestive system: 2 trials led